Health Care [ 3/12 ] | Health Care Technology [ 45/75 ]
NASDAQ | Common Stock
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific.
It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes.
It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes.
In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool.
Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software.
Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 26 | 0.09 Decreased by -40.00% | 0.11 Decreased by -20.28% |
| Nov 6, 25 | 0.14 Increased by +7.69% | 0.11 Increased by +27.39% |
| Aug 6, 25 | 0.07 Increased by 0.00% | 0.10 Decreased by -30.00% |
| May 5, 25 | 0.03 Decreased by -70.60% | 0.11 Decreased by -74.07% |
| Feb 26, 25 | 0.15 Increased by +66.67% | 0.13 Increased by +19.62% |
| Nov 6, 24 | 0.13 Increased by +18.18% | 0.11 Increased by +18.18% |
| Aug 6, 24 | 0.07 Decreased by -41.67% | 0.10 Decreased by -30.00% |
| May 7, 24 | 0.10 Decreased by -16.67% | 0.10 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 103.65 M Increased by +3.28% | -5.89 M Decreased by -189.63% | Decreased by -5.69% Decreased by -186.79% |
| Sep 30, 25 | 104.62 M Increased by +10.33% | 1.52 M Increased by +211.23% | Increased by +1.46% Increased by +200.82% |
| Jun 30, 25 | 104.57 M Increased by +12.06% | -1.97 M Increased by +84.35% | Decreased by -1.88% Increased by +86.03% |
| Mar 31, 25 | 106.00 M Increased by +9.67% | 4.74 M Increased by +201.28% | Increased by +4.47% Increased by +192.35% |
| Dec 31, 24 | 100.36 M Increased by +14.03% | 6.58 M Increased by +152.80% | Increased by +6.55% Increased by +146.30% |
| Sep 30, 24 | 94.82 M Increased by +10.80% | -1.37 M Increased by +97.20% | Decreased by -1.45% Increased by +97.47% |
| Jun 30, 24 | 93.31 M Increased by +3.17% | -12.57 M Decreased by -367.19% | Decreased by -13.48% Decreased by -358.99% |
| Mar 31, 24 | 96.65 M Increased by +7.04% | -4.68 M Decreased by -444.85% | Decreased by -4.85% Decreased by -422.18% |